PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
No Data
No Data available this quarter, please select a different quarter.
1.94
Net debt 50-75% of AGEN's 3.86. Mohnish Pabrai would check if this competitive advantage in leverage translates to better reinvestment opportunities.
No Data
No Data available this quarter, please select a different quarter.
1.21
Current ratio below 50% of AGEN's 3.54. Jim Chanos would check for potential working capital crisis.
No Data
No Data available this quarter, please select a different quarter.